CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Standard
CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges. / Pacia, Danielle M.; Brown, Beatrice L.; Minssen, Timo; Darrow, Jonathan.
I: Journal of Law and the Biosciences, Bind 11, Nr. 1, 26.01.2024.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges
AU - Pacia, Danielle M.
AU - Brown, Beatrice L.
AU - Minssen, Timo
AU - Darrow, Jonathan
PY - 2024/1/26
Y1 - 2024/1/26
N2 - Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability
AB - Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability
U2 - https://doi.org/10.1093/jlb/lsad030
DO - https://doi.org/10.1093/jlb/lsad030
M3 - Journal article
VL - 11
JO - Journal of Law and the Biosciences
JF - Journal of Law and the Biosciences
SN - 2053-9711
IS - 1
ER -
ID: 307030282